Trial · NCT07507825
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
NCT07507825, Phase 2, Not yet recruiting, First People's Hospital of Hangzhou
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG). Trials, record NCT07507825. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07507825
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
- NCT number
- NCT07507825
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 61 participants, estimated
- Lead sponsor
- First People's Hospital of Hangzhou
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Intervention for Venetoclax, Intervention for Homoharringtonine, Intervention for Azacitidine, Intervention for G-CSF
- First posted
- 2026-04-02
- Last updated
- 2026-04-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CRc（CR+CRi） | After 2 cycles of induction therapy(each cycle is 28 days; approximately Day 56) | Composite complete remission (CR) plus CR with incomplete hematologic recovery |
| Secondary | ORR（CR+CRi+MLFS+PR） | After 2 cycles of induction therapy(each cycle is 28 days; approximately Day 56) | Objective Response Rate (Complete Response + Complete Response with incomplete hematologic recovery + Marrow Leukemia-Free State + Partial Response) |
| Secondary | OS | 1year | Overall Survival |
| Secondary | RFS | 1year | Relapse-Free Survival |
| Secondary | MRD | After 2 cycles of induction therapy(each cycle is 28 days; approximately Day 56) | Rate of negative conversion of evaluable minimal residual disease (MRD) |
| Secondary | NCICTCAEv5.0 | After 2 cycles of induction therapy(each cycle is 28 days; approximately Day 56) | Safety: Hematologic and non-hematologic toxicities (NCI CTCAE v5.0) |
| Other | EBS | After 2 cycles of induction therapy(each cycle is 28 days; approximately Day 56) | Exploratory biomarker assessment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07507825
GET https://conductscience.org/api/trials/v1/NCT07507825/registered